PapersPMID:34238308
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
NMN zwitterionNo finding here moved its endpoint.
What did not
1 findingHow to read these marks →“No significant changes in HRmax, RERmax, HRR, O2-pulse, peak power, peak workload, ∆O2/∆WR, or VO2max were shown between the control and any of the NMN treatment groups.”
- Study
- RCT
- Duration
- 6 weeks
- Interests
- Industry funded
- Dose studied
- NMN powder 150, 300 or 600 mg twice daily (300, 600, 1200 mg/day) vs matching placebo powder (cranberry powder and maltodextrin), taken before training
- Population
- Healthy recreationally trained amateur runners aged 27-50 years, all arms in a 6-week aerobic training programme; three NMN dose groups (300, 600 and 1200 mg/day) compared with a placebo group, pooled statement across the dose groups
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- healthy recreationally trained amateur runners
- Participants
- 48
- Comparator
- placebo
- Duration
- 42 days
- Endpoints measured
- 50